Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PNT2258

Known as: DNA Interference Oligonucleotide PNT2258 
A liposomal formulation of the 24-mer oligonucleotide PNT100, with potential antineoplastic activity. PNT2258 targets and complements to… Expand
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

PNT100

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Unintended target effect of anti-BCL-2 DNAi
Introduction Previous research suggested that a novel compound PNT2258 inhibits B-cell lymphoma 2 (BCL-2) transcription by DNA… Expand
  • figure 1
  • figure 2
  • figure 3
2016
2016
PNT2258, a novel deoxyribonucleic acid inhibitor, induces cell cycle arrest and apoptosis via a distinct mechanism of action: a new class of drug for non-Hodgkin's lymphoma
Current therapy for BCL-2-associated tumors such as Non-Hodgkin Lymphomas (NHL) is inadequate. The DNAi PNT2258, a 24 base single… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2016
2016
A phase 2 study of PNT2258 in patients with relapsed or refractory (r/r) diffuse large b-cell lymphoma (DLBCL): An initial report from the Wolverine study.
TPS7577Background: PNT2258, a liposomal encapsulated DNA interference (DNAi) oligonucleotide nanoparticle targeting the BCL2… Expand
Review
2016
Review
2016
Hematologic malignancies: newer strategies to counter the BCL-2 protein
IntroductionBCL-2 is the founding member of the BCL-2 family of apoptosis regulatory proteins that either induce (pro-apoptotic… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
2014
2014
Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide
PNT100 is a 24-base, chemically unmodified DNA oligonucleotide sequence that is complementary to a region upstream of the BCL-2… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2014
2014
Pharmacokinetics of the BCL2-targeted DNA interference (DNAi) nanoparticle PNT2258 in patients with recurrent or refractory non-Hodgkin lymphoma.
2586 Background: PNT2258 contains PNT100, a DNA interference (DNAi) oligonucleotide encapsulated in a lipid nanoparticle. PNT2258… Expand
Highly Cited
2013
Highly Cited
2013
A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors
PurposeMaximum tolerated dose, safety, pharmacokinetics, and pharmacodynamics were assessed in this phase 1 study of PNT2258, a… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
2013
2013
The BCL2 Targeted Deoxyribonucleic Acid Inhibitor (DNAi) PNT2258 Is Active in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma
Background Aberrant BCL2 control mechanisms are a defining characteristic of a variety of cancers including follicular lymphoma… Expand
2013
2013
Abstract 3529: Effect of PNT2258, an anti-BCL2 DNA-interference drug, on tumor growth and immunological markers in mice and humans.
Background: The dysregulation of apoptosis is a defining characteristic of malignant cells where excessive concentration of BCL2… Expand
2012
2012
Abstract 2764: Effect of PNT2258 combinations with docetaxel, dacarbazine, or vemurafenib on the A375 melanoma xenograft
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Bcl-2 and bcl-XL are anti-apoptotic proteins that… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE